Surgery in Preventing Ovarian Cancer in Patients With Genetic Mutations
Public ClinicalTrials.gov record NCT02760849. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
WISP (Women Choosing Surgical Prevention)
Study identification
- NCT ID
- NCT02760849
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Not applicable
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Enrollment
- 374 participants
Conditions and interventions
Conditions
- Deleterious BARD1 Gene Mutation
- Deleterious BRCA1 Gene Mutation
- Deleterious BRCA2 Gene Mutation
- Deleterious BRIP1 Gene Mutation
- Deleterious EPCAM Gene Mutation
- Deleterious MLH1 Gene Mutation
- Deleterious MSH2 Gene Mutation
- Deleterious MSH6 Gene Mutation
- Deleterious PALB2 Gene Mutation
- Deleterious PMS2 Gene Mutation
- Deleterious RAD51C Gene Mutation
- Deleterious RAD51D Gene Mutation
- Hereditary Breast and Ovarian Cancer Syndrome
- Premenopausal
Interventions
- Laboratory Biomarker Analysis Other
- Oophorectomy Procedure
- Quality-of-Life Assessment Other
- Salpingectomy Procedure
- Salpingo-Oophorectomy Procedure
Other · Procedure
Eligibility (public fields only)
- Age range
- 30 Years to 50 Years
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 1, 2016
- Primary completion
- May 30, 2041
- Completion
- May 30, 2041
- Last update posted
- Jan 6, 2026
2016 – 2041
United States locations
- U.S. sites
- 9
- U.S. states
- 8
- U.S. cities
- 8
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Chicago Comprehensive Cancer Center | Chicago | Illinois | 60637 | — |
| Dana-Farber Cancer Institute | Boston | Massachusetts | 02215 | — |
| Mayo Clinic | Rochester | Minnesota | 55905 | — |
| Siteman Cancer Center at Washington University | St Louis | Missouri | 63110 | — |
| Laura and Isaac Perlmutter Cancer Center at NYU Langone | New York | New York | 10016 | — |
| Memorial Sloan Kettering Cancer Center | New York | New York | 10065 | — |
| University of Pennsylvania/Abramson Cancer Center | Philadelphia | Pennsylvania | 19104 | — |
| M D Anderson Cancer Center | Houston | Texas | 77030 | — |
| University of Washington Medical Center | Seattle | Washington | 98195 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02760849, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 6, 2026 · Synced May 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02760849 live on ClinicalTrials.gov.